Recommended Dose of Cixutumumab for Children with Recurrent Solid Tumors Determined
the Cancer Therapy Advisor take:
Cixutumumab is a monoclonal antibody that has potent anti-tumor activity in a variety of cell-lines and xenografts, so researchers from the Cincinnati Children’s Hospital Medical Center and other institutions sought to determine the maximum-tolerated dose and dose-limiting toxicities of the drug when administered in combination with temsirolimus to children with tumors that are refractory to therapy.
In this study, which was published online ahead of print in Clinical Cancer Research, cixutumumab and temsirolimus were given intravenously once every 7 days in 28-day cycles to 39 patients with a median age of 11.8 years.
Four dose levels of cixutumumab and temsirolimus were given (6 mg/kg and 15 mg/m2; 6 mg/kg and 10 mg/m2; 4 mg/kg and 8 mg/m2; and 6 mg/kg and 8 mg/m2 ) and of those patients enrolled in the trial, 33 were assessable for resulting toxicities.
Mucositis was the predominant dose-limiting toxicity. Other toxicities included hypercholesterolemia, fatigue, thrombocytopenia, and increased ALT. Based on the PK parameters of the study, the authors concluded that the recommended doses for a future phase II study of cixutumumab and temsirolimus are 6 mg/kg and 8 mg/m2, respectively.
Cixutumumab is a monoclonal antibody that has potent anti-tumor activity in a variety of cell-lines and xenografts.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed